83214-11-3

Usage

Uses

Used in Pharmaceutical Industry:
[[(2R,3R,4S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[(2R)-2,3-dioctadecanoyloxypropoxy]phosphinic acid is used as a potential candidate for drug development due to its complex structure and the presence of various functional groups. [[(2R,3R,4S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3,4-dihydroxy-oxolan2-yl]methoxy-hydroxy-phosphoryl]oxy-[(2R)-2,3-dioctadecanoyloxypropoxy ]phosphinic acid's ability to form interactions with biopolymers and macromolecules makes it a promising candidate for the creation of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, [[(2R,3R,4S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[(2R)-2,3-dioctadecanoyloxypropoxy]phosphinic acid can be utilized as a key intermediate or building block for the synthesis of more complex molecules. Its unique structure, including the pyrimidine base, sugar molecule, and phosphinic acid groups, can be exploited to create novel compounds with specific properties and applications.
Used in Drug Delivery Systems:
[[(2R,3R,4S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3,4-dihydroxy-oxolan2-yl]methoxy-hydroxy-phosphoryl]oxy-[(2R)-2,3-dioctadecanoyloxypropoxy ]phosphinic acid's structure, which includes long-chain fatty acid esters, suggests potential use in drug delivery systems. It could be employed as a carrier or component in the development of targeted drug delivery platforms, enhancing the bioavailability and therapeutic efficacy of various pharmaceutical agents.

InChI:InChI=1/C48H89N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-43(52)61-37-40(64-44(53)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)38-62-67(57,58)66-68(59,60)63-39-41-45(54)46(55)47(65-41)51-36-35-42(49)50-48(51)56/h35-36,40-41,45-47,54-55H,3-34,37-39H2,1-2H3,(H,57,58)(H,59,60)(H2,49,50,56)/t40-,41-,45-,46+,47-/m1/s1

Upstream product

• 17966-16-4 1,2-Distearoyl-sn-glycero-3-phosphoric acid 
• 816-94-4 distearoylphosphatidylcholine 

Relevant academic research and scientific papers

Phospholipid-Nucleoside Conjugates. 3. Syntheses and Preliminary Biological Evaluation of 1-β-D-Arabinofuranosylcytosine 5'-Monophosphate-L-1,2-Dipalmitin and Selected 1-β-D-Arabinofuranosylcytosine 5'-Diphosphate-L-1,2-Diacylglycerols

Several new phospholipid-ara-C conjugates have been prepared and tested as prodrugs of the parent ara-C.The new derivatives include ara-CMP-L-dipalmitin, ara-CDP-L-distearin, ara-CDP-L-dimyristin, ara-CDP-L-diolein, and the radioactively labeled derivative ara-CDP-L-dipalmitin.In addition, the unusually stable ara-CMP-L-dipalmitin-N-phosphoryldicyclohexylurea adduct was isolated as a crystalline solid (two diastereoisomers) in the reaction sequence to prepare ara-CMP-L-dipalmitin.The new prodrugs were solubilized by sonication methods and tested for their antiproliferative activity in vitro against mouse myeloma MPC-11 cells and against L1210 lymphoid leukemia.Such studies demonstrated that the antiproliferative activities of the prodrugs (as determined by ED50) were less that ara-C on a molar basis.In the mouse myeloma cell line some evidence was obtained that the antiproliferative activity was related to the chain length of the fatty acid side chains in the prodrugs.In in vivo studies against L1210 lymphoid leukemia in mice, the prodrugs were shown to be much more effective than ara-C, with the overall efficacy apparently being independent of the length of the fatty acid side chain.Some evidence was obtained in the in vivo studies that the ara-CDP-L-dimyristin which bears the shortest fatty acid side chain was more toxic at the higher dosages than the longer chain length derivatives.